FOLH1 and prostate cancer: Initial diagnostic imaging technologies, including ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI), provided several indications of abnormalities; however, PSMA PET/CT was instrumental in confirming the presence of primary prostate cancer and extensive metastases and assisting in precise staging and following appropriate therapeutic regimens for the disease.